Acucela announced that the novel investigational visual cycle modulator emixustat hydrochloride failed to reduce geographic atrophy lesion growth rate in the SEATTLE study, according to a company press release. There was no significant difference ... Healio, 2 months ago
Acucela terminates Emixustat, OPA-6566 agreement with Otsuka Pharmaceutical - Bio Spectrum Asia, 1 month ago
Acucela Announces Termination of Emixustat Agreement and OPA-6566 Agreement with Otsuka Pharmaceutical, and Postponement of Annual Shareholder Meeting - Benzinga.com, 1 month ago
Leaders see beyond anti-VEGF monotherapy. BY JERRY HELZNER, CONTRIBUTING EDITOR ■ Leading developers of drugs for retinal disease — including Regeneron, Roche/Genentech, and Aerpio — are pursuing what could become one of the most promising ...Retinal Physician, 1 week ago
May's top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial
US-based companies ProMedica and Stemedica Cell Technologies (Stemedica), along with the family of hockey legend Gordie Howe, have planned to begin a human stem cell trial to advance the treatment of traumatic brain injury (TBI). The three-year ...Drug Development Technology, 1 month ago
on your WebpageAdd Widget >Get your members hooked!